Agios Pharmaceuticals vs Kymera Therapeutics
Agios Pharmaceuticals is the larger business, with $54.0m of revenue in fiscal 2025 against $39.2m for Kymera Therapeutics (1.4 times as much). Agios Pharmaceuticals grew faster (48.0% against -16.7%). Agios Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -764.0% against -794.0%. Agios Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Agios PharmaceuticalsAGIO, 2025 | Kymera TherapeuticsKYMR, 2025 |
|---|---|---|
| Revenue | $54.0m | $39.2m |
| Revenue growth | 48.0% | -16.7% |
| Net income | −$413m | −$311m |
| Operating margin | -873.9% | -891.1% |
| Net margin | -764.0% | -794.0% |
| Return on equity | -30.2% | -25.8% |
| Free cash flow | −$377m | −$234m |
| Cash | $89.1m | $357m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 539 | 238 |
| Market value | $1.87bn | $10.94bn |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 40 sales | 2 buys, 274 sales |